Cresco Labs Q2 revenue beats estimates

Cresco Labs

06/08/2026 11:41

Overview
U.S. cannabis products seller's Q2 revenue rose, beats analyst expectations
Adjusted EBITDA for Q2 grew 20% sequentially to $40 mln
Company announced CFO is stepping down, interim appointment made

Outlook
Company expects federal cannabis rescheduling to improve business economics and capital markets access

Result Drivers
ACQUIRED DISPENSARIES - Co said improved gross profit at newly acquired Pennsylvania dispensaries drove Q2 growth
NEW STORE OPENINGS - Co said new Sunnyside locations in Ohio were among highest-performing new openings statewide
FEDERAL REFORM IMPACT - Co said federal cannabis rescheduling and removal of 280E tax restrictions improved business economics

Company press release: ID:nBw8tS66ha

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$173.34 mln
$166.32 mln (5 Analysts)
Q2 Net Income
 
$15.37 mln
 
Q2 Adjusted EBITDA
 
$40 mln
 
Q2 Adjusted Gross Margin
 
51.60%
 
Q2 Gross Profit
 
$87 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Cresco Labs Inc is C$2.40, about 166.7% above its August 5 closing price of C$0.90

Reuters Recommended Reads
Aug 5 - Curaleaf Q2 revenue beats analyst estimates on domestic growth
Aug 5 - Verano Q2 revenue tops estimates on retail expansion
Aug 4 - Green Thumb Q2 revenue beats estimates on Minnesota adult-use launch

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)